Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a pioneering clinical-stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products. These novel drugs aim to treat significant diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is at the forefront of creating the first therapeutics that induce a shift towards health by enhancing the microbiome's biology.
The company operates primarily in the United States, leveraging its microbiome therapeutics platform to develop Ecobiotic™ microbiome therapeutics. These therapies are designed to restore health by repairing the function of a dysbiotic microbiome, particularly in the colon. Seres' lead product, SER-109, is developed to prevent the recurrence of Clostridium difficile infection (CDI), a severe infection of the colon. Additional product candidates include SER-262, SER-287, and SER-401.
Recently, Seres announced the sale of its VOWST assets to Nestlé Health Science under a non-binding memorandum of understanding. This transaction will provide Seres with capital infusions, including an upfront payment, and is expected to be completed in the next 90 days, subject to shareholder approval and other conditions. VOWST, the first FDA-approved oral microbiome therapy, prevents the recurrence of CDI in adults following antibacterial treatment for recurrent CDI.
Seres plans to use the capital from this transaction to retire its existing debt and strengthen its financial position. The company is also advancing SER-155, evaluated in a Phase 1b study in patients undergoing allogeneic hematopoietic stem cell transplantation. SER-155 has the potential to reduce gastrointestinal and related bloodstream infections, as well as acute graft-versus-host disease.
Seres Therapeutics continues to innovate in microbiome therapeutics, aiming to benefit multiple underserved patient groups, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The company's approach could protect millions of medically vulnerable patients from life-threatening infections while addressing the global public health issue of antimicrobial resistance (AMR).
Seres Therapeutics (MCRB) announced its fourth quarter and full year 2021 financial results, reporting a net loss of $65.6 million for the year, improving from a loss of $89.1 million in 2020. Significant progress was noted in the Phase 3 ECOSPOR III study of SER-109 for recurrent C. difficile infection (rCDI), achieving its primary endpoint. A Biologics License Application (BLA) filing is anticipated in mid-2022, potentially making SER-109 the first microbiome therapeutic approved. The company also launched SER-155 for Infection Protection and reported cash reserves of approximately $291.2 million.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on March 1, 2022, at 8:30 a.m. ET to discuss its Q4 2021 and full-year results, along with a general business update. Investors can join by calling 844-277-9450 for domestic or 336-525-7139 for international access, referencing conference ID 6277858. The event will also be available for live streaming on their website. Seres' SER-109 program achieved positive clinical results and has received FDA Breakthrough Therapy and Orphan Drug designations, targeting recurrent C. difficile infection.
Seres Therapeutics (Nasdaq: MCRB) announced that CEO Eric Shaff will present at the Chardan Metagenomics and Microbiome Medicines Summit on March 1, 2022, at 2:00 p.m. ET. An audio webcast of the presentation will be available on the company's website, with a replay accessible one hour post-event for 21 days. Seres is a pioneer in microbiome therapeutics, with its SER-109 program showing promising results for treating C. difficile infections. The company is also conducting Phase 1b studies for SER-301 and SER-155 targeting ulcerative colitis and infection prevention, respectively.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced the appointment of Paula Cloghessy as Executive Vice President and Chief People Officer effective February 7, 2022. Her extensive 20+ years in HR within biotechnology and pharmaceuticals aims to enhance the company’s culture and support its growth, particularly in advancing SER-109 towards FDA approval. Cloghessy emphasizes talent development and employee engagement, ensuring a positive work environment. This strategic hiring comes as Seres continues its pioneering efforts in microbiome therapeutics.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a webcast investor event on January 31, 2022, from 8:30 a.m. to 10:00 a.m. ET, focusing on microbiome therapeutics for infection protection. Clinical data from the Phase 3 ECOSPOR III trial showed that SER-109 significantly reduced CDI recurrence, with 88% of patients achieving a sustained clinical response. Additionally, SER-155 is being evaluated in patients at risk of serious infections. The event will feature discussions on new infection prevention strategies and the role of microbiome therapeutics.
Seres Therapeutics (MCRB) announced significant results from its Phase 3 ECOSPOR III study on SER-109, an oral microbiome therapeutic for recurrent C. difficile infection. The study demonstrated an 88% sustained clinical response in patients taking SER-109, compared to 60% with placebo. Furthermore, SER-109 was well tolerated, mirroring placebo safety profiles. The company plans to finalize its Biologics License Application (BLA) filing by mid-2022, aiming for FDA approval. These findings published in the New England Journal of Medicine highlight SER-109's potential to transform treatment standards for rCDI.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 8:15 a.m. ET. A live audio webcast will be available on the company's website, with a replay accessible one hour post-event for 21 days. Seres focuses on microbiome therapeutics, showcasing its SER-109 program, which received Breakthrough Therapy and Orphan Drug designations from the FDA for treating recurrent C. difficile infections. Additionally, SER-301 and SER-155 are under evaluation in clinical studies for ulcerative colitis and gastrointestinal infections.
Seres Therapeutics (NASDAQ: MCRB) reported preliminary findings from the Phase 2b ECO-RESET study of SER-287 for treating ulcerative colitis, revealing successful engraftment of bacterial species. Despite the primary endpoints not being met, engraftment results were statistically significant (p ≤ 0.001). The company is exploring potential biomarker-based patient selection for future trials. Ongoing analysis of SER-287 and SER-301 data is expected to guide further development steps in ulcerative colitis.
Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced the enrollment of the first patient in its SER-155 Phase 1b clinical study, aimed at reducing infections, mortality, and graft-versus-host disease (GvHD) in patients undergoing hematopoietic stem cell transplantation (HSCT). SER-155, a microbiome therapeutic, targets antibiotic-resistant infections and aims to enhance microbiome diversity to improve patient outcomes. Collaborating with prestigious institutions like Memorial Sloan Kettering Cancer Center and The University of Chicago, the trial will assess both safety and effectiveness in approximately 70 patients.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that President and CEO Eric Shaff will be participating in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The chat will be available for on-demand viewing on the company’s website. Seres is at the forefront of microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results for treating recurrent C. difficile infection and receiving FDA Breakthrough Therapy designation. The company is also advancing additional programs for ulcerative colitis and gastrointestinal infections.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
What does Seres Therapeutics, Inc. do?
What is SER-109?
What recent transaction did Seres Therapeutics announce?
What is VOWST?
What is the financial condition of Seres Therapeutics?
Who founded Seres Therapeutics?
What other products are in Seres Therapeutics' pipeline?
What partnerships does Seres Therapeutics have?
What is the company's approach to treating diseases?
Where can I find more information about Seres Therapeutics?
